← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $166B	1,743	-4	-0.2%	$130B
2	2 Amgen AMGN $230B	1,223	+37	+3%	$86.9B
3	3 Eli Lilly LLY $1.08T	1,042	+13	+1%	$54.7B
4	4 Becton Dickinson BDX $51.5B	847	-4	-0.5%	$18.5B
5	5 McKesson MCK $114B	818	+3	+0.4%	$38.4B
6	6 Teva Pharmaceutical Industries Limited TEVA $47.5B	773	-7	-0.9%	$27B
7	7 Conagra Brands CAG $6.61B	632	-10	-2%	$9.86B
8	8 DaVita DVA $11.5B	474	+3	+0.6%	$13B
9	9 Regeneron Pharmaceuticals REGN $80.1B	474	+26	+6%	$25.9B
10	10 Novo Nordisk NVO $168B	470	-3	-0.6%	$9.17B
11	11 AstraZeneca AZN $251B	402	-17	-4%	$5.75B
12	12 ResMed RMD $33.1B	301	-12	-4%	$3.59B
13	13 Herbalife HLF $1.49B	255	-33	-11%	$4.33B
14	14 Accendra Health ACH $24.1M	224	-18	-7%	$1.98B
15	15 West Pharmaceutical WST $26.4B	213	-9	-4%	$2.96B
16	16 Opko Health OPK $1.02B	183	+8	+5%	$636M
17	17 MannKind Corp MNKD $971M	176	-2	-1%	$553M
18	18 Dr. Reddy's Laboratories RDY $10.6B	159	-10	-6%	$1.32B
19	19 DELISTED WW International WW	146	-2	-1%	$1.62B
20	20 Tootsie Roll Industries TR $2.87B	144	-4	-3%	$376M
21	21 Fresenius Medical Care FMS $11.5B	130	-2	-2%	$453M
22	22 Medifast MED $132M	124	-8	-6%	$340M
23	ARNA 23 DELISTED Arena Pharmaceuticals Inc ARNA	121	-8	-6%	$453M
24	24 Lexicon Pharmaceuticals LXRX $712M	104	+5	+5%	$657M
25	25 Alaunos Therapeutics TCRT $5.26M	94	+2	+2%	$127M